Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice

Figures & data

Figure 1 Proportion of patients with headache relief 2 hours after lasmiditan infusion.

Note: Ferrari MD, Färkkilä M, Reuter U, et al, Cephalalgia, volume 30(10), pages 1170–1178, copyright © 2010 by SAGE Publications. Reprinted by Permission of SAGE Publications, Ltd.³⁰
Abbreviation: PBO, placebo.

Table 1 Summary of results from COL MIG-201

IV dose	2.5 mg IV	5 mg IV	10 mg IV	20 mg IV	30 mg IV	45 mg IV	Placebo
Number of study subjects	4	12	24	28	16	4	42
2 hours headache pain freedom (%)	0 (0)	0 (0)	5 (20.8)	8 (28.8)	6 (37.5)	1 (25)	8 (19)
Headache pain relief (%)	2 (50)	2 (16.7)	13 (54.2)	18 (64.3)	11 (68.8)	3 (75)	19 (45.2)
Dizziness n (%)	2 (50.0)	1 (8.3)	8 (33.3)	7 (25.0)	3 (18.8)	1 (25.0)	6 (14.3)
Paresthesia n (%)	0	0	5 (20.8)	8 (28.8)	7 (43.8)	1 (25.0)	0
Fatigue n (%)	0	1 (8.3)	1 (4.2)	5 (17.9)	3 (18.8)	0 (0%	4 (9.5)

Note: Ferrari MD, Färkkilä M, Reuter U, et al, Cephalalgia, volume 30(10), pages 1170–1178, copyright © 2010 by SAGE Publications. Reprinted by Permission of SAGE Publications, Ltd.³⁰

Table 2 Results summary of COL MIG-202, SAMURAI, and SPARTAN

Oral dose	50 mg	100 mg	200 mg	400 mg	Placebo
COL MIG-202
Number of subjects:	79	81	69	68	81
2 hours headache pain freedom (%)	13.9	13.6	18.8a	27.9a	7.4
Headache pain relief (%)	43.0a	64.1b	50.7b	64.7b	25.9
SAMURAI
2 hours headache pain freedom (%)	----	28.2b	32.2b	----	15.3
MBS freedom (%)	----	40.9b	40.7b	----	29.5
SPARTAN
2 hours headache pain freedom (%)	28.6b	31.4b	38.8b	----	21.3
MBS freedom (%)	40.8b	44.2b	48.7	----	33.5

Notes: Headache pain relief at 2 hours. Data from these studies.^31–33

a P<0.05 (compared to placebo).

b P<0.005 (compared to placebo).

Abbreviation: MBS, most bothersome symptoms.

Table 3 Summary of side effects

Study name Dose	COL MIG-202 (P 11)					SAMURAI (P II)			GLADIATOR (P III)
	50 mg	100 mg	200 mg	400 mg	Placebo	100 mg	200 mg	Placebo	100 mg	200 mg
n	82	82	71	70	86	630	609	617	558	597
Dizziness n (%)	20 (24.3)	29 (35.4)	29 (35.4)	38 (54.2)	0 (0)	75 (11.9)	95 (15.4)	19 (3.1)	36 (48)	40 (67)
Paresthesia n (%)	3(3.6)	11 (13.4)	16 (22.5)	29 (27.1)	2 (2.3)	36 (5.7)	46 (7.6)	13 (2.1)	7 (15)	1 (2)
Somnolence n (%)	11 (13.4)	12 (14.6)	10 (14.0)	10 (14.2)	3 (3.5)	33 (5.2)	32 (5.3)	14 (2.3)	2 (2)	8 (12)
Fatigue n (%)	15 (18.2)	24 (29.3)	26 (36.6)	23 (32.9)	3 (3.5)	24 (3.8)	18 (3)	1 (0.2)	14 (16)	10 (17)
Nausea n (%)	7(8.5)	8 (9.8)	3 (4.2)	5 (7.1)	0 (0)	16 (2.5)	29 (4.8)	9 (1.5)	15 (21)	18 (39)
Lethargy n (%)	----	----	----	----	----	12 (1.9)	14 (2.3)	1 (0.2)	4 (4)	5 (7)

Note: Data from these studies.^31,32,34

Abbreviation: P, phase of clinical trial.

FerrariMDFärkkiläMReuterUAcute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trialCephalalgia201030101170117820855362

 PubMed Web of Science ®Google Scholar

FärkkiläMDienerHCGéraudGEfficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging studyLancet Neurol201211540541322459549

 PubMed Web of Science ®Google Scholar

Lilly Announces Positive Results for Second Phase 3 Study of Lasmidi-tan for the Acute Treatment of Migraine (NYSE:LLY); 2018 Available from: https://investor.lilly.com/static-files/15cf1efc-da8f-485c-9001-6ff3b432b129Accessed March 19, 2018

 Google Scholar

SAMURAI: Lasmiditan Reduces Pain in Acute Migraine2018 Available from: https://globenewswire.com/news-release/2016/09/06/869611/0/en/CoLucid-Pharmaceuticals-Announces-Achievement-of-Both-Primary-and-Key-Secondary-Endpoints-in-the-SAMURAI-Phase-3-Pivotal-Trial-of-Lasmiditan-in-Migraine.htmlAccessed March 19, 2018

 Google Scholar

CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR [webpage on the Internet]GlobeNewswire, Inc.2016 Available from: https://globenewswire.com/news-release/2016/09/19/872772/0/en/CoLucid-Pharmaceuticals-Provides-Interim-Update-on-GLADIATOR.htmlAccessed August 10, 2018

 Google Scholar